ANI Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $148,332 | $138,040 | $137,430 | $131,654 |
Gross Profit | 85,257 | 65,645 | 73,587 | 63,040 |
EBITDA | -13,419 | 23,725 | 29,741 | 23,905 |
EBIT | -29,167 | 9,028 | 15,055 | 8,711 |
Net Income | -24,166 | -2,287 | 18,207 | 1,155 |
Net Change In Cash | 148,332 | 138,040 | 137,430 | 131,654 |
Free Cash Flow | 7,031 | 12,965 | 13,688 | 39,961 |
Cash | 144,982 | 240,110 | 228,597 | 221,121 |
Basic Shares | 19,404 | 19,321 | 19,422 | 19,219 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $486,816 | $316,385 | $216,136 | $208,475 |
Gross Profit | 305,303 | 177,600 | 115,526 | 121,318 |
EBITDA | 106,599 | 48,068 | -1,684 | 29,068 |
EBIT | 46,808 | -8,904 | -48,936 | -15,570 |
Net Income | 18,779 | -47,896 | -42,603 | -22,548 |
Net Change In Cash | 486,816 | 316,385 | 216,136 | 208,475 |
Cost of Revenue | -52,067 | 92,434 | -54,494 | |
Free Cash Flow | 100,448 | -47,658 | -20,316 | -53,055 |
Cash | 221,121 | 48,228 | 100,300 | 7,864 |
Basic Shares | 18,194 | 16,260 | 12,596 | 11,964 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $1.34 |
2024-06-30 | $1.02 |
2024-03-31 | $1.21 |
2023-12-31 | $1 |
